Clinical Trials
2 trialsNCT07005102 2026-06-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT07001748 2026-05-15
STOPGAP II
Eastern Cooperative Oncology Group
Phase 2/3 Recruiting